KIDSHealthcare · Medical DevicesThe 7 Wall Street analysts covering OrthoPediatrics Corp. hold a median 12-month price target of $30 — -2.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 31 Oct 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores OrthoPediatrics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (85): Sales and profits are climbing, and climbing faster than before.
Issuance (33): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on KIDS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −2.8% from it.
Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Oct 2026 | BTIG | Maintains | Buy | $29 → $30 |
| 28 Oct 2026 | Canaccord Genuity | Maintains | Buy | $28 → $30 |
| 28 Oct 2026 | Lake Street | Maintains | Buy | $34 → $38 |
| 28 Oct 2026 | Piper Sandler | Reiterates | Overweight | $25 → $30 |
| 28 Oct 2026 | Stifel | Maintains | Buy | $24 → $27 |
| 28 Oct 2026 | TD Cowen | Maintains | Buy | $23 → $28 |
| 28 Oct 2026 | Truist Securities | Maintains | Hold | $22 → $28 |
| 14 Sept 2026 | BTIG | Reiterates | Buy | — |
| 14 Sept 2026 | BTIG | Reiterates | Buy | $29 |
| 20 Aug 2026 | BTIG | Maintains | Buy | — |
| 20 Aug 2026 | BTIG | Maintains | Buy | $24 → $29 |
| 5 Aug 2026 | Needham | Maintains | Buy | — |
| 5 Aug 2026 | Needham | Maintains | Buy | $30 → $35 |
| 5 Aug 2026 | Piper Sandler | Reiterates | Overweight | — |
| 5 Aug 2026 | Piper Sandler | Reiterates | Overweight | $22 → $25 |
| 16 July 2026 | Truist Securities | Maintains | Hold | — |
| 16 July 2026 | Truist Securities | Maintains | Hold | $17 → $20 |
| 1 May 2026 | BTIG | Reiterates | Buy | — |
| 1 May 2026 | BTIG | Reiterates | Buy | $24 |
| 2 Mar 2026 | Truist Securities | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
KIDS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, OrthoPediatrics Corp. returned +87.4% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 3% of US stocks
Cheaper than 39% of US stocks
Cheaper than 37% of US stocks
Cheaper than 1% of US stocks
Higher than 67% of US stocks
Higher than 54% of US stocks
Higher than 87% of US stocks
Higher than 27% of US stocks
Higher than 18% of US stocks
Higher than 36% of US stocks
Higher than 36% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
OrthoPediatrics Corp. has a market value of $806.0M and an enterprise value of $872.7M.
Revenue in the twelve months to 30 June 2026: $252.7M. The latest quarter grew 18.6% year on year.
Net income over the same four quarters: −$39.7M, a −15.7% net margin.
Diluted earnings per share, trailing twelve months: $−1.68.
Free cash flow in the twelve months to 30 June 2026: −$1.8M.
Trailing P/E: 246.3×; forward P/E: −40.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
OrthoPediatrics Corp. employs 602 people — $420K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own OrthoPediatrics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
OrthoPediatrics (KIDS) was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The excerpt says this might drive the stock higher in the near term.
Why it matters — KIDS watchers may note the improved Zacks rating as a reflection of increased optimism about the company's earnings prospects.
OrthoPediatrics held its third-quarter 2026 earnings call on October 27, 2026. The excerpt lists company executives and participating analysts but provides no financial results or management commentary.
Why it matters — KIDS watchers can note the call took place, but this excerpt contains no substantive updates on the company’s performance.
OrthoPediatrics raised its 2026 revenue guidance to $270 million to $273 million. Third-quarter revenue increased 19% year over year to $72.7 million.
Why it matters — The updated guidance and quarterly growth provide KIDS watchers with current information on the company’s revenue outlook and performance.
OrthoPediatrics reported record third-quarter revenue and raised its full-year sales outlook. It cited broad-based demand across its trauma, deformity, scoliosis and specialty bracing businesses, alongside continued progress from recently introduced products.
Why it matters — The record revenue and higher sales outlook provide KIDS watchers with an update on demand across the company’s businesses and product progress.
OrthoPediatrics reported a third-quarter loss of $0.23 per share, compared with the Zacks consensus estimate of a $0.25 loss and a $0.24 loss a year earlier. The headline also says the company topped revenue estimates.
Why it matters — KIDS watchers may note that the reported per-share loss was smaller than the consensus estimate and the headline reports revenue above estimates.
The 7 Wall Street analysts covering OrthoPediatrics Corp. have a median 12-month price target of $30, with estimates ranging from $27 to $38. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering OrthoPediatrics Corp., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OrthoPediatrics Corp. 79 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, OrthoPediatrics Corp. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies -2.8% from the last close, and Ticker Nerd's factor model ranks OrthoPediatrics Corp. 79 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering OrthoPediatrics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KIDS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $38 over the next 12 months.
OrthoPediatrics Corp. returned +87.4% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
OrthoPediatrics Corp. is a medical device company focused exclusively on pediatric orthopedics.
The most recent item we track (Zacks Investment Research, 30 Oct 2026): "All You Need to Know About OrthoPediatrics (KIDS) Rating Upgrade to Buy". OrthoPediatrics (KIDS) was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The excerpt says this might drive the stock higher in the near term.
OrthoPediatrics Corp. is a medical device company focused exclusively on pediatric orthopedics. It designs, develops, and markets anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions, supporting surgeons and caregivers in treating trauma and deformity correction, scoliosis, and sports medicine cases. The company’s product portfolio includes surgical systems, pediatric nailing solutions, spinal care products, and specialty bracing technologies tailored to the needs of smaller and developing patients. OrthoPediatrics also operates orthopedic and prosthetic clinic services, extending its role beyond products to non-surgical care. Its business is centered on serving hospitals, children’s medical centers, and orthopedic specialists in the United States and international markets. Headquartered in Warsaw, Indiana, OrthoPediatrics occupies a specialized position in the medical technology market as a pediatric-only orthopedic platform.
CEO Mr. David R. Bailey · 602 employees · United States · https://www.orthopediatrics.com
